Shionogi (4507.T)

Executive Summary

Shionogi & Co., Ltd. is a Japanese pharmaceutical company with over 140 years of history and a strong legacy in antibiotic innovation. The company focuses on infectious diseases, including antimicrobial resistance, HIV, influenza, and COVID-19, leveraging its expertise in small molecules and strategic partnerships. Its pipeline features several late-stage and approved products, such as the antibiotic cefiderocol (approved in multiple regions for Gram-negative infections) and naldemedine for opioid-induced constipation. Shionogi also has early- to mid-stage programs in Pompe disease (S-606001) and CNS disorders (BPN14770). With a diversified portfolio and a commitment to unmet medical needs, Shionogi is well-positioned in the infectious disease space. However, its growth is tempered by reliance on relatively mature products and a modest pipeline of novel first-in-class assets. The company's financial stability and global partnerships provide a solid foundation for sustained R&D investment.

Upcoming Catalysts (preview)

• Q3 2026Cefiderocol label expansion for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP)80% success
• Q4 2027Phase 2 data readout for S-606001 in Pompe disease40% success
• Q2 2026Initiation of Phase 2 trial for BPN14770 in Alzheimer's disease or cognitive impairment50% success